Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/19/2026 | $75.00 | Buy | Citigroup |
| 5/11/2026 | $69.00 | Neutral | Goldman |
| 4/27/2026 | $120.00 | Overweight | Morgan Stanley |
| 1/28/2026 | $80.00 | Overweight | Barclays |
| 1/20/2026 | $98.00 | Hold → Buy | Canaccord Genuity |
| 12/3/2025 | $60.00 | Outperform → Market Perform | Leerink Partners |
| 11/6/2025 | $61.00 | Buy → Hold | Stifel |
| 9/8/2025 | $60.00 | Neutral | H.C. Wainwright |
Study met primary endpoint, exceeding expectations with a highly statistically significant improvement in annualized growth velocity (AGV, change from baseline) of 2.33 cm/yr compared to placebo at week 52, as well as statistically significant increases in standing height and height Z-score Study demonstrated statistically significant improvement in arm span at week 52 compared to placebo, a key measure linked to functional independenceSafety findings consistent with the established profile in achondroplasia with no new safety signals identifiedSupplemental New Drug Application (sNDA) submission to U.S. Food and Drug Administration (FDA) planned for third quarter, followed by submissions to
ENERGY 3 study met 1 of 2 co-primary endpoints in children with ENPP1 deficiency Treatment with BMN 401 led to statistically significant increases in plasma inorganic pyrophosphate (PPi) concentration, one of the study's co-primary endpoints; however, no improvement was observed in Radiographic Global Impression of Change (RGI-C) scores, the study's other co-primary endpoint and an important clinical measure of change in rickets severity Company is evaluating data to determine next steps SAN RAFAEL, Calif., May 18, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced results from the pivotal Phase 3 ENERGY 3 trial evaluating BMN 401 in children aged 1-12 with ENPP1
Financing to accelerate 4D Path's pipeline of treatment predictive biomarkers in solid tumors. 4D Path adds two seasoned healthcare executives to strengthen its board and accelerate growth. Ms. Stultz to serve as 4D Path Board Chair 4D Path, a company dedicated to personalizing cancer care through a novel, physics-informed approach to predict tumor response to therapy, today announced the first close of a strategic financing round to accelerate the development of treatment predictive biomarkers for 4D Path-sponsored clinical use and partnerships with Biopharma companies. 4D Path's strategy is to develop digital treatment prediction biomarkers that inform more clear and accurate treatmen
10-Q - BIOMARIN PHARMACEUTICAL INC (0001048477) (Filer)
8-K - BIOMARIN PHARMACEUTICAL INC (0001048477) (Filer)
8-K - BIOMARIN PHARMACEUTICAL INC (0001048477) (Filer)
Citigroup initiated coverage of BioMarin Pharmaceutical with a rating of Buy and set a new price target of $75.00
Goldman resumed coverage of BioMarin Pharmaceutical with a rating of Neutral and set a new price target of $69.00
Morgan Stanley resumed coverage of BioMarin Pharmaceutical with a rating of Overweight and set a new price target of $120.00
For Immediate Release: June 29, 2023 Today, the U.S. Food and Drug Administration approved Roctavian, an adeno-associated virus vector-based gene therapy for the treatment of adults with severe hemophilia A without pre-existing antibodies to adeno-associated virus serotype 5 detected by an FDA-approved test. “Hereditary hemophilia A is a potentially serious bleeding disorder. Severe cases of hemophilia A can ca
4 - BIOMARIN PHARMACEUTICAL INC (0001048477) (Issuer)
4 - BIOMARIN PHARMACEUTICAL INC (0001048477) (Issuer)
4 - BIOMARIN PHARMACEUTICAL INC (0001048477) (Issuer)
First Quarter 2026 Total Revenues Increased Year-over-year to $766 millionIncreased Full-year 2026 Total Revenues Guidance to between $3.825 billion and $3.925 billion, Representing Accelerated Growth Rate of 20% Y/Y at the Midpoint, and Reflecting the Addition of GALAFOLD® and POMBILITI® + OPFOLDA® to BioMarin's PortfolioConference Call and Webcast Scheduled Today at 4:30 p.m. ETSAN RAFAEL, Calif., May 4, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced financial results for the first quarter ended March 31, 2026. "With the acquisition of Amicus T
SAN RAFAEL, Calif., April 27, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Monday, May 4, 2026, at 4:30 p.m. ET to discuss first quarter 2026 financial results and provide a general business update. Dial-in Number U.S. / Canada Dial-in Number: 800-715-9871International Dial-in Number: 646-307-1963Conference Call ID: 3424435 U.S. / Canada Replay Dial-in Number: 800-770-2030International Replay Dial-in Number: 609-800-9909Playback I
Full-year 2025 Total Revenues Increased 13% Y/Y to $3.2 Billion, Led by 9% Revenue Growth for Enzyme Therapies and 26% Revenue Growth for VOXZOGO®Fourth Quarter 2025 Total Revenues Increased 17% Y/Y Led by 13% Revenue Growth for Enzyme Therapies and 31% Revenue Growth for VOXZOGOAnnounced Definitive Agreement to Acquire Amicus Therapeutics, including Galafold® for Fabry Disease and Pombiliti® + Opfolda® for Pompe Disease; Expected to Significantly Accelerate and Diversify RevenuesBioMarin Provides 2026 Guidance Excluding any Post-Close Contribution from the Announced Acquisition of Amicus, Anticipated to Close in Q2'26Conference Call and Webcast Scheduled Today at 4:30 p.m. ETSAN RAFAEL, Cal
Financing to accelerate 4D Path's pipeline of treatment predictive biomarkers in solid tumors. 4D Path adds two seasoned healthcare executives to strengthen its board and accelerate growth. Ms. Stultz to serve as 4D Path Board Chair 4D Path, a company dedicated to personalizing cancer care through a novel, physics-informed approach to predict tumor response to therapy, today announced the first close of a strategic financing round to accelerate the development of treatment predictive biomarkers for 4D Path-sponsored clinical use and partnerships with Biopharma companies. 4D Path's strategy is to develop digital treatment prediction biomarkers that inform more clear and accurate treatmen
Ian T. Clark elected Chair of the Board; Richard A. Meier to retire SAN RAFAEL, Calif., April 21, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) said today that the Board of Directors has appointed Ian T. Clark as Chair of the Board, subject to his election at the company's Annual Meeting of Stockholders on June 2, 2026. Mr. Clark will succeed Richard A. Meier, who is retiring after two decades on the Board, and the appointment will become effective immediately following the Annual Meeting. Mr. Clark joined BioMarin's Board in 2025 and brings extensive board, go
Mr. Davé Brings more than 20 Years of Experience in Creating Enterprise Value through Digital Transformation, Information Technology and Artificial Intelligence across the Biopharmaceutical Industry SAN RAFAEL, Calif., Jan. 12, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced it has appointed Arpit Davé as Executive Vice President, Chief Digital and Information Officer, a new position reporting directly to President and Chief Executive Officer Alexander Hardy. Mr. Davé will be responsible for reimagining and executing BioMarin's enterprise technology strategy, data science and digital transformation to help create value for patients, employees and shareholders.
SC 13G - BIOMARIN PHARMACEUTICAL INC (0001048477) (Subject)
SC 13G/A - BIOMARIN PHARMACEUTICAL INC (0001048477) (Subject)
SC 13G/A - BIOMARIN PHARMACEUTICAL INC (0001048477) (Subject)